NCT03316222View on ClinicalTrials.gov

Study of GNS561 in Patients With Liver Cancer

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 4, 2018

Primary Completion Date

January 15, 2021

Study Completion Date

April 25, 2022

Conditions
Hepatocellular CarcinomaCholangiocarcinoma, Intrahepatic
Interventions
DRUG

GNS561

Escalating doses to be administered 3 times a week.

Trial Locations (5)

10065

Memorial Sloan Kettering, New York

38043

CHU Grenoble, Grenoble

69004

Croix-Rousse Hospital, Lyon

75014

Saint-Joseph Hospital, Paris

Unknown

Jules Bordet Institute, Brussels

Sponsors

Lead Sponsor

Genoscience Pharma
All Listed Sponsors
lead

Genoscience Pharma

INDUSTRY

NCT03316222 - Study of GNS561 in Patients With Liver Cancer | Biotech Hunter | Biotech Hunter